OP09
Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801)
liquid, clone PAb1801, Calbiochem®
Sign Into View Organizational & Contract Pricing
All Photos(1)
UNSPSC Code:
12352203
NACRES:
NA.43
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
PAb1801, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
should not react with
mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... TP53(7157)
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 Ag14 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A-431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801) is validated for use in Frozen Sections, Gel Shift, Immunoblotting, IP, Paraffin Sections for the detection of p53 (Ab-2) (Pantropic).
Immunogen
Epitope: within amino acids 46-55 of human p53
Human
a human p53 fusion protein
Application
Frozen Sections (5 µg/ml)
Gel Shift (see comments)
Immunoblotting (2.5 µg/ml)
Immunoprecipitation (1 µg/sample)
Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)
Gel Shift (see comments)
Immunoblotting (2.5 µg/ml)
Immunoprecipitation (1 µg/sample)
Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
Analysis Note
Negative Control
SK-OV-3 cells or normal skin
SK-OV-3 cells or normal skin
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Other Notes
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Wild-type p53 has a short half-life and is present in low amounts in cells. For immunoprecipitation, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53; short incubation times with 35S-Met (≤ 1 h) will help reduce background. For immunoblots of wild-type p53, maximize sensitivity by preconcentrating samples by immunoprecipitation with Cat. No. OP09, then immunoblot using Cat. No. PC35 and chemiluminescent detection. For a gel shift assay, use Cat. No. OP09L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
nwg
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
James G Jackson et al.
Cancer cell, 21(6), 793-806 (2012-06-16)
Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical response compared to tumors with wild-type p53. Doxorubicin-treated
Timothy C Hallstrom et al.
Proceedings of the National Academy of Sciences of the United States of America, 100(19), 10848-10853 (2003-09-05)
Previous work has demonstrated a role for the E2F1 gene product in signaling apoptosis, both as a result of the deregulation of the Rb/E2F pathway as well as in response to DNA damage. We now show that the ability of
Timothy Budden et al.
Oncotarget, 7(38), 60940-60953 (2016-08-04)
UVB exposure leads to DNA damage, which when unrepaired induces C>T transitions. These mutations are found throughout the melanoma genome, particularly in non-transcribed regions. The global genome repair (GGR) branch of nucleotide excision repair (NER) is responsible for repairing UV-induced
Shou-Ching Tang et al.
Breast cancer research and treatment, 84(3), 203-213 (2004-03-18)
BAG-1, a recently identified anti-apoptotic protein, is overexpressed in the majority of invasive breast carcinomas. Overexpression of BAG-1 is important for both multi-step oncogenesis and resistance of cancer cells to apoptosis induced by DNA-damaging alkylating agents. BAG-1 protein species are
N Shinoura et al.
British journal of cancer, 86(4), 587-595 (2002-03-01)
Mutation of the p53 gene plays a critical role in the development of cancer and response to cancer therapy. To analyze the mechanism of cancer development and to improve cancer therapy, it is important to assess which genes are downstream
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service